Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Indivior PLC

Latest From Indivior PLC

Industry Could Influence ICER With Better-Targeted Comments, Tufts Researchers Suggest

Institute for Clinical and Economic Review's cost effectiveness reports usually don't change much following input from drug sponsors, researchers at Tufts conclude.

Health Technology Assessment Comparative Effectiveness

Pink Sheet Podcast: The Upcoming US FDA Commissioner Confirmation Hearing, Sublocade Loses Orphan Designation, Project Orbis Politics

Pink Sheet reporters look ahead to Stephen Hahn's Senate confirmation hearing, review the revocation of Indivior's buprenorphine orphan designation and consider Richard Pazdur's comments about external issues affecting Project Orbis.
Leadership Review Pathway

US FDA Revokes Orphan Drug Designation For Indivior’s Sublocade

In first-of-its-kind decision, agency concludes it relied on unreasonable assumptions regarding total market size, and failed to consider information about other dosage formulations, in granting designation for buprenorphine under the cost recovery provision; however, the FDA reaffirms that scope of Sublocade’s three-year exclusivity will keep Braeburn’s Brixadi off the market for another year.

Legal Issues FDA

Gottlieb: Brand Industry 'Gaming' Tactics Have Shifted

US FDA's focus on areas such as REMS abuse may have prompted certain brand sponsors to shift their focus to the commercial space to keep generic competition off the market, former commissioner Scott Gottlieb tells the Association for Accessible Medicines.

Generic Drugs Risk Management
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Reckitt Benckiser Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Indivior PLC
  • Senior Management
  • Shaun Thaxter, CEO
    Mark Crossley, CFO
    Ponni Subbiah, MD, CMO
    Christian Heidbreder, PhD, CSO
    Richard Simkin, Chief Commercial Officer
  • Contact Info
  • Indivior PLC
    Phone: (0)1753 217800
    215 Bath Rd.
    Slough, SL1 4AA